Eccogene
Cambridge, US · Founded 2018 · 32 employees on LinkedIn · 1 known investors
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.
Investors · 1
Frequently asked questions
- What does Eccogene do?
- Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.
- Who are Eccogene's investors?
- Eccogene's investors include Delos Capital.
- Where is Eccogene headquartered?
- Eccogene is headquartered in Cambridge, US.